American International Group Inc. boosted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 8.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,138 shares of the biopharmaceutical company’s stock after buying an additional 844 shares during the period. American International Group Inc.’s holdings in Ocular Therapeutix were worth $103,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Janney Montgomery Scott LLC purchased a new position in shares of Ocular Therapeutix during the first quarter worth approximately $110,000. Parametric Portfolio Associates LLC raised its position in shares of Ocular Therapeutix by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 401 shares during the last quarter. Teachers Advisors LLC raised its position in shares of Ocular Therapeutix by 47.7% in the fourth quarter. Teachers Advisors LLC now owns 37,318 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 12,050 shares during the last quarter. GWM Advisors LLC purchased a new position in shares of Ocular Therapeutix during the first quarter worth approximately $381,000. Finally, NEXT Financial Group Inc purchased a new position in shares of Ocular Therapeutix during the first quarter worth approximately $480,000. Institutional investors and hedge funds own 65.04% of the company’s stock.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) traded down 1.21% on Friday, reaching $5.71. The company’s stock had a trading volume of 21,897 shares. Ocular Therapeutix, Inc. has a 12 month low of $4.82 and a 12 month high of $11.91. The company has a 50-day moving average price of $7.40 and a 200 day moving average price of $8.64. The company’s market cap is $165.74 million.
Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by $0.05. Ocular Therapeutix had a negative return on equity of 101.03% and a negative net margin of 3,005.52%. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.51 million. During the same period last year, the firm posted ($0.46) EPS. Ocular Therapeutix’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts anticipate that Ocular Therapeutix, Inc. will post ($2.21) EPS for the current fiscal year.
WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/11/american-international-group-inc-purchases-844-shares-of-ocular-therapeutix-inc-nasdaqocul.html.
A number of brokerages recently commented on OCUL. ValuEngine lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. HC Wainwright set a $10.00 target price on Ocular Therapeutix and gave the company a “buy” rating in a research note on Wednesday, August 2nd. BTIG Research restated a “neutral” rating on shares of Ocular Therapeutix in a research note on Thursday. Cantor Fitzgerald cut their target price on Ocular Therapeutix from $35.00 to $21.00 and set an “overweight” rating for the company in a research note on Wednesday, July 12th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $8.00 target price (down from $16.00) on shares of Ocular Therapeutix in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $20.11.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL).
What are top analysts saying about Ocular Therapeutix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ocular Therapeutix Inc. and related companies.